Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes
{{output}}
Objective: A majority of adults with type 1 diabetes (T1D) are overweight (OW) or obese (OB) and often struggle to reach glycemic targets. Tirzepatide, a dual-incretin approved for type 2 diabetes (T2D) and OW/OB, has been shown ... ...
